1. 362 A PhII study of bemcentinib, a first-in-class selective AXL kinase inhibitor, in combination with pembrolizumab in pts with previously-treated advanced NSCLC: Updated clinical & translational analysis. (9th November 2020) Authors: Spicer, James; Helland, Åslaug; Carcereny, Enric; Arriola, Edurne; Gomez, Manuel Dómine; Trigo Perez, Jose Manuel; Thompson, Jonathan; Strauss, James; Ortega Granados, Ana Laura; Felip, Enriqueta; Schmidt, Emmett; Chisamore, Michael; Madeleine, Noelly; Rayford, Austin; Lorens, Katherine; Siddiqui... Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A387 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 362 A PhII study of bemcentinib, a first-in-class selective AXL kinase inhibitor, in combination with pembrolizumab in pts with previously-treated advanced NSCLC: Updated clinical & translational analysis. (9th November 2020) Authors: Spicer, James; Helland, Åslaug; Carcereny, Enric; Arriola, Edurne; Gomez, Manuel Dómine; Trigo Perez, Jose Manuel; Thompson, Jonathan; Strauss, James; Ortega Granados, Ana Laura; Felip, Enriqueta; Schmidt, Emmett; Chisamore, Michael; Madeleine, Noelly; Rayford, Austin; Lorens, Katherine; Siddiqui... Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A221 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 790 A phase II study (TACTI-002) of eftilagimod alpha (a soluble LAG-3 protein) with pembrolizumab in PD-L1 unselected patients with metastatic non-small cell lung(NSCLC) or head and neck carcinoma(HNSCC). (10th December 2020) Authors: Krebs, Matthew; Majem, Margarita; Felip, Enriqueta; Forster, Martin; Doger, Bernard; Clay, Tim; Carcereny, Enric; Peguero, Julio; Horn, Leora; Bajaj, Pawan; Roxburgh, Patricia; Brignone, Chrystelle; Mueller, Christian; Triebel, Frederic Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A472 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 790 A phase II study (TACTI-002) of eftilagimod alpha (a soluble LAG-3 protein) with pembrolizumab in PD-L1 unselected patients with metastatic non-small cell lung(NSCLC) or head and neck carcinoma(HNSCC). (9th November 2020) Authors: Krebs, Matthew; Majem, Margarita; Felip, Enriqueta; Forster, Martin; Doger, Bernard; Clay, Tim; Carcereny, Enric; Peguero, Julio; Horn, Leora; Bajaj, Pawan; Roxburgh, Patricia; Brignone, Chrystelle; Mueller, Christian; Triebel, Frederic Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A839 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer. (November 2020) Authors: Walls, Gerard M.; Oughton, Jamie B.; Chalmers, Anthony J.; Brown, Sarah; Collinson, Fiona; Forster, Martin D.; Franks, Kevin N.; Gilbert, Alexandra; Hanna, Gerard G.; Hannaway, Nicola; Harrow, Stephen; Haswell, Tom; Hiley, Crispin T.; Hinsley, Samantha; Krebs, Matthew; Murden, Geraldine; Phillip,... Journal: Clinical and translational radiation oncology Issue: Volume 25(2020) Page Start: 61 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. CONCORDE: a phase Ib platform study of novel agents in combination with conventional radiotherapy in non-small cell lung cancer (NSCLC). (March 2022) Authors: Horne, Ashley; Ali, Aaisha; Brown, Sarah; Butterworth, Karl; Chalmers, Anthony; Clipson, Alexandra; Collinson, Fiona; Dive, Caroline; Faivre-Finn, Corinne; Forster, Martin; Franks, Kevin; Gilbert, Alexandra; Hanna, Gerry; Hannaway, Nicola; Harrow, Stephen; Hartley, John; Hiley, Crispin; Jones, Ro... Journal: Lung cancer Issue: Volume 165(2022)Supplement 1 Page Start: S69 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Cumulative Antibiotic Use Significantly Decreases Efficacy of Checkpoint Inhibitors in Patients with Advanced Cancer. (10th July 2019) Authors: Tinsley, Nadina; Zhou, Cong; Tan, Grace; Rack, Samuel; Lorigan, Paul; Blackhall, Fiona; Krebs, Matthew; Carter, Louise; Thistlethwaite, Fiona; Graham, Donna; Cook, Natalie Journal: Oncologist Issue: Volume 25:Number 1(2020) Page Start: 55 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗